anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fluticasone Propionate and Salmeterol Inhalation Powder USP

250 mcg/50 mcg is supplied as a disposable gray plastic inhaler containing a foil blister strip with 60 blisters. The inhaler is packaged in a plastic-coated, moisture-protective foil pouch (NDC 68788-8453-6).

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Store in a dry place away from direct heat or sunlight. Keep out of reach of children. 

Fluticasone propionate and salmeterol inhalation powder should be stored inside the unopened moisture-protective foil pouch and only removed from the pouch immediately before initial use. Discard fluticasone propionate and salmeterol inhalation powder 1 month after opening the foil pouch or when the counter reads “0” (after all blisters have been used), whichever comes first. The inhaler is not reusable. Do not attempt to take the inhaler apart.
The invention relates to application of lycium bararum polysaccharide in the prevention of urinary calculus. The lycium bararum polysaccharide is a main active ingredient in Chinese wolfberry, has antioxidation effect, and can remove free radicals in human bodies. The experiment shows that a proper amount of lycium bararum polysaccharide can reduce the formation of renal calcium oxalate calculus of a rat who drinks a stone-inducing agent, and an action mechanism of the lycium bararum polysaccharide can reduce the damage of the free radicals to kidney tissues through an antioxidation reaction, thereby reducing the apoptosis of renal tubular epithelial cells. Therefore, the lycium bararum polysaccharide has the efficacy of preventing the urinary calculus, and also has important application in the fields of medicine, food and health care products. The lycium bararum polysaccharide synchronously has various remarkable health care functions and the characteristic of homology of medicine and food, and has the advantages of low cost, convenient taking, and high compliance of patients. At the same time, the lycium bararum polysaccharide belongs to a pure natural substance and has no any side effect.
A non-transitory computer readable storage medium has instructions executed by a processor to prompt a user for personal information. The user is prompted to take a self-image. The user is prompted to take an image of a user identification card. Correspondence between the self-image and a user identification card image is validated. The user record is finalized. Health test results are obtained. A digital health certificate is created if the health test results are verified. A user image from on premise location is received. Health certification criteria for the user is applied to alternately establish a criteria met state and a criteria fail state. Premise access denied messages are sent in response to the criteria fail state. A safety certification is supplied in response to the criteria met state.
An apparatus and method for providing a medical protocol graphic user interface is provided. The apparatus and method generates a plurality of graphic images representing a medical treatment plan. The graphic images are presented in a chronological order based on real or virtual time slots and may be viewed in either a flow chart or a chart view format. The view chart format may be used by healthcare professionals to enter data. The graphical images include an order node, result node and flow node. The various nodes may be connected to form a healthcare plan assigned to a patient. Costs may be assigned to each order and various costs of various treatments may be determined. Patient plans may be transferred or modified by other healthcare professionals.
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to docetaxel and berbamine double-load drug chitosan nanoparticles and a preparation method thereof. According to the nanoparticles, docetaxel and nicotinamide are prepared into eutectic crystals, and then chitosan nanoparticles are covered with the eutectic crystals and berbamine at the same time. According to the oral taking nanoparticles, the eutectic crystals are formed by nicotinamide and a main drug, and the water solubility of nicotinamide is improved. The sensibilization of berbamine is utilized for promoting apoptosis of cancer cells; chitosan is utilized for prolonging the retention time of the drug in the body and reducing the in-vivo clearance rate of the drug. Docetaxel, berbamine and chitosan are combined for use and prepared into the nanoparticles, the nanoparticles are absorbed by the gastrointestinal tract after being orally taken, and the function of remarkably improving the oral taking bioavailability of paclitaxel is achieved. The preparation method of the nanoparticles is simple, the production cost is low, and mass production is easy.
The objective of this study is to test the safety of the ICVP system and the feasibility of eliciting visual percepts in response to electrical stimulation in persons with blindness. The electrical stimulation is provided by wireless floating microelectrode arrays (WFMAs) that are part of the ICVP system. The WFMAs are implanted in the visual cortex. Five participants will take part in the study and each participant will have multiple WFMA devices implanted in their visual cortex on one side of the brain. After recovery from surgery, participants will begin a series of tests to assess the ability of electrical stimulation to induce visual percepts and how these percepts may provide some measure of artificial vision. Weekly participant testing will occur over a period of one to three years.
PURPOSE:To provide the titled agent for promoting the transcutaneous absorption of a drug and useful as a component of a drug composition for external application, by using at least one kind of an aliphatic hydrocarbon ester of 2- pyrrolidone-5-carboxylic acid as an active component. CONSTITUTION:The objective assistant for promoting the transcutaneous absorption of a drug contains at least one kind of the compound selected from the aliphatic hydrocarbon esters of 2-pyrrolidone-5-carboxylic acid (e.g. pyrrolidonecarboxylic acid methyl ester). Any drug applicable to the skin can be used as the drug to be compounded with said assistant. A drug for local action (e.g. procaine hydrochloride) can be impregnated deep in the skin, and a drug for systemic action (e.g. indomethacin) can be transferred rapidly to the blood. The absorption promoting effect can be improved by the combined use with a hydrophilic compound (e.g. methyl alcohol) in the case of a 1-5C hydrocarbon ester, or with a hydrophobic compound (e.g. n-hexane) in the case of a >=6C hydrocarbon ester.
Spinal cord injury (SCI) is a devastating disease and often leads to lifelong disability, muscle spasm, sensory deficits, autonomic disturbances, as well as bowel and bladder incontinence, all of which can cause tremendous troubles to patients but are lack of any effective treatment up to now. SCI is not only a severe healthy problem but also a great social burden. To the best of our knowledge, cell therapy seems to be a promising alternative for the treatment of SCI due to numerous advantages. However, cytotherapy is still in its infancy since there are many disparities and uncertainties regarding subject selection, cellular type, transplantation timing, administration dose and deliver route in clinical trial protocols. Hence, a standardized well-designed clinical study is urgently required for the safe and effective treatment of SCI.

In this study, complete or incomplete cervical, thoracic, and thoracolumbar SCI subjects were recruited to join in a prospective, single-center, single-arm clinical trial. Intervention is four times of subarachnoid administration of allogeneic hUC-MSCs. During the intervention and follow-up periods of this trial, any adverse event was identified rapidly and managed properly. The maximum intensity and relationship of any adverse event with hUC-MSCs administration were identified.The primary efficacy indicator is American spinal injury association (ASIA) total score at the fourth follow-up and SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) total score at the fourth follow-up. Secondary efficacy indicators are these two indicators at the remaining time points, scores of pin prick, light touch, motor and sphincter, muscle spasticity and spasm, autonomic system, bladder and bowel functions, residual urine volume. Subgroup analysis of primary efficacy indicators was also performed.

In this trial, informed consent forms that had the approval of the institutional review board were obtained from all participants before recruitment. In this clinical study, subarachnoid transplantation of hUC-MSCs was performed a total of four times per subject with the delivery dose of 1×10E6 cells/kg. After the completion of cytotherapy, subject was regularly followed up in the hospital at four time points, determined at 1, 3, 6, and 12 months following the final administration of hUC-MSCs. At each time point of administration (the first, second, third, and fourth transplantation) and follow-up (the first, second, third, and fourth follow-up), safety and efficacy indicators were collected accordingly by two independent assessors.
Decades of efforts in elucidating pain mechanisms, including pharmacological, neuroanatomical, and physiological studies have provided insights into how nociceptive information transmits from the periphery to the brain and the locations receiving nociceptive signals. However, little is known about which specific stimulus-dependent activated neurons, amongst heterogeneous neural environments, discriminatively evoke the cognate pain behavior. We here shed light on the population of neurons in the spinal cord activated by a painful stimulus to identify chronic pain-dependent activated neuronal subsets using Fos2A-iCreER (TRAP2) mice. We have found a large number of neurons activated by a normally nonpainful stimulus in the spinal cord of spinal nerve-ligated mice, compared with sham. Neuronal activation was observed in laminae I and II outer under heat hyperalgesia. A large number of neurons in laminae II inner were activated in both mechanical allodynia and heat hyperalgesia conditions, while mechanical allodynia tends to be the only stimulus that activates cells at lamina II inner dorsal region. Neuroanatomical analyses using spinal cell markers identified a large number of spinal inhibitory neurons that are recruited by both mechanical allodynia and heat hyperalgesia. Of interest, spinal neurons expressing calretinin, calbindin, and parvalbumin were activated differently with distinct pain modalities (ie, mechanical allodynia vs heat hyperalgesia). Chemogenetic inhibition of those activated neurons significantly and specifically reduced the response to the pain stimulus associated with the stimulus modality originally given to the animals. These findings support the idea that spinal neuronal ensembles underlying nociceptive transmission undergo dynamic changes to regulate selective pain responses.
Compositions and methods relating to paraoxonase fusion polypeptides are disclosed. In some aspects, the fusions are bispecific molecules that include a first biologically active polypeptide linked amino-terminal to a biologically active paraoxonase (e.g., human PON1 or a variant thereof), wherein the first biologically active polypeptide is a DNase, an RNase, a SOD1, a CTLA-4 extracellular domain, a CD40 extracellular domain, or a polypeptide that specifically binds and neutralizes an inflammatory cytokine. Bispecific fusions may further include a second biologically active polypeptide (e.g., a dimerizing domain or a domain that specifically binds to the neonatal Fc receptor (FcRn)) linked carboxyl-terminal to the first biologically active polypeptide and amino-terminal to the paraoxonase. In other aspects, a fusion polypeptide includes a biologically active paraoxonase linked carboxyl-terminal or amino-terminal to a dimerizing or FcRn-binding domain. In certain variations, a dimerizing or FcRn-binding domain is an immunoglobulin Fc region. Also disclosed are dimeric proteins comprising first and second paraoxonase fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.
Part G of the study will explore the tolerability and PK profile of oral ETX0282 when administered either as a single dose (i.e., 300 mg as a single dose) or in 4 equal, divided doses over a 6 hour period (i.e., 75 mg every 2 hours for 4 doses \[a 300 mg total dose\]) when administered in a fasted state. Participants will receive the 2 treatments in a cross-over design according to one of 2 randomized sequences: AB or BA. Treatment A: 0 hours, 4 × 75 mg ETX0282/placebo; 2, 4, and 6 hours, 1 × 75 mg placebo. Treatment B: 0 hours, 1 × 75 mg ETX0282/placebo and 3 × 75 mg placebo; 2, 4, and 6 hours, 1 × 75 mg ETX0282/placebo. Participants will be confined to the Study Unit from Day -1 and discharged following collection of the 24 hours post Day 4 dose assessments (Day 5).
PROBLEM TO BE SOLVED: To obtain an O/W emulsion-type cosmetic composition excellent in temperature stability and water resistance or water repellency and containing an inorganic pigment in a stably dispersed state by compounding a specific polyglycerine fatty acid ester with a specific acyllactic acid or its salt, and a specific amino acid salt. SOLUTION: This cosmetic composition is obtained by compounding a polyglycerine fatty acid ester having a degree of polymerization of >=4, an acyllactic acid having a >=8C acyl group or its salt and a basic amino acid salt of a >=8C fatty acid. HLB of the ester is preferably <=8. The fatty acid residue of the acyllactic acid or its salt is preferably a fatty acid having at least one kind selected from saturated, unsaturated and branched fatty acids and hydrophilic substituting groups. The weight ratio of the ester to the acyllactic acid or its salt is preferably 1:20 to 20:1. The content of the basic amino acid salt is preferably 0.1-10wt.% based on a cosmetic. The toxicity of the cosmetic is low, and the cosmetic is safe to a human body since it is produced of a surfactant having excellent biodegradability.
This is a prospective; double-blind randomized controlled study performed in the HKWC. Recruited subjects include subjects ≥50 years and adult subjects ≥18 years with chronic illness. Eligible subjects will be randomly allocated (3:3:2) into one of the three groups in the first year. Group IQ: topical 5% 250mg imiquimod ointment followed by intradermal QIV, Group IM: topical aqueous-cream followed by IM QIV and Group HD: topical aqueous-cream followed by intramuscular high-dose TIV. Hemagglutination inhibition and neutralization antibody titres will be assayed. We plan to recruit 4000 subjects, 1500 subjects in each of the IQ and IM group (500 subjects in each subgroup with 3 subgroups) and 1000 subjects for the HD group (500 subjects in each subgroup with 2 subgroups).

In the following year, the IQ and IM groups will be further randomized equally into three subgroups: IQ1, IQ2 and IQ3; IM1, IM2 and IM3; and two subgroups for HD group: HD1 and HD2. Subjects randomized to IQ1, IM1 will receive the QIV with the same topical treatment, delivery mode and vaccine as the first year and HD1 will receive the TIV with the same topical treatment, delivery mode and vaccine as the first year. Subgroup IQ2 and IM2 will be vaccinated as follow: IQ2 will receive topical aqueous-cream followed by IM QIV, IM2 will receive topical imiquimod ointment followed by ID QIV. Subgroup IQ3, IM3, HD2 will receive normal saline as the vaccine for that year, but delivered by the same mode and topical treatment. In the third year, subgroups IQ1, IQ2, IM1, IM2 and HD1 will receive the same topical treatment, delivery mode and vaccine as the second year. Subgroup IQ3, IM3 and HD2 will receive the same topical treatment, delivery mode and vaccine as the first year.
There are total 40 subjects in 18-59 age group. Among them, 30 subjects were randomly assigned to the experimental group and the control group in a 2:1 ratio. In addition, other 10 subjects aged 18-55 to receive the experimental vaccine as the serum calibration test population.
Atrial fibrillation (AF) is a prevalent cardiac arrhythmia, with recent research indicating a correlation between immune system characteristics and the development of AF. However, it remains uncertain whether the immunological response is the primary underlying component or a secondary consequence of AF. Initially, we investigated the effect of immune cells on AF by performing forward Mendelian randomization (MR) analyses with immune cells as the exposure variable and their associated genetic variants as instrumental variables. Subsequently, we performed reverse MR analyses with AF as the exposure variable and immune cells as the outcome variable to exclude the interference of reverse causality, to distinguish between primary and secondary effects, and to further elucidate the causal relationship between the immune system and AF. We discovered that membrane proteins on specific immune cells, such as CD25 on memory B cells-which functions as a part of the interleukin-2 receptor-may be risk factors for AF development, with odds ratios of 1.0233 (95% confidence interval: 1.0012-1.0458, P = .0383). In addition, certain immune cell counts, such as the CD4 regulatory T cell Absolute Count, play a protective factor in the development of AF (odds ratio: 0.9513, 95% confidence interval: 0.9165-0.9874; P = .0086). More detailed results are elaborated in the main text. Our MR study has yielded evidence that substantiates a genetically inferred causal association between the immune system and AF. Identifying the risk factors associated with AF is vital to facilitate the development of innovative pharmaceutical treatments.
An embodiment in accordance with the present invention provides a system and method for determining cardiac events. The system and method include using an imaging modality to obtain a cardiac image of the subject. The image is then used to determine the subject's systolic, post-systolic, and early diastolic strain peaks. Additionally, a strain rate index (SRI) value is computed for the subject using the systolic, post-systolic, and early diastolic strain peaks. The SRI value can then be used to determine a level of risk of cardiac failure. Further, a likelihood of atrial fibrillation can also be determined. The SRI value and risk of cardiac event can then be used to create a treatment plan for the subject, if necessary.
Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite. Afterwards, depending on allocations, in the laser devices group, adjuvant treatment approaches were be performed by means of laser devices either photodynamic therapy (HELBO, Photodynamic Systems GmbH), or high power diode laser (940nm, Biolase).
Incorporating genetic testing in routine outpatient nephrology clinic can improve on chronic kidney disease (CKD) diagnosis and utilization of precision medicine. We sent a genetic test on patients with atypical presentation of common kidney diseases, electrolytes derangements, and cystic kidney diseases. We were able to identify a gene variant contributing to patients' kidney disease in more than half of our cohort. We then showed that patients with ApoL1 risk allele have likely worse kidney disease, and we were able to confirm genetic focal segmental glomerulosclerosis (FSGS) in 2 patients and avoid unnecessary immunosuppression. Genetic testing has also improved our operation to establish a polycystic kidney disease excellence center by confirming our diagnosis, especially in patients without a well-defined family history. In conclusion, utilizing genetic testing in a routine outpatient renal clinic did not cause any burden to either patients or nephrologists, with minimal administrative effort and no financial cost to our patients. We expect that genetic testing in the right setting should become routine in nephrology to achieve a patient-centered precision medicine with less invasive means of kidney disease diagnosis.
Use of the iTClamp50 will be determined by the EMS and ER physicians. Patients who have received treatment will be tracked from pre-hospital to patient discharge (chart review). EMS care providers and physicians will answer a survey about their experience with the iTClamp50.
This study explores using AI for detecting lymph node metastasis in breast cancer, aiming to analyze extensive medical imaging data. AI assists clinicians in identifying metastases and formulating precise treatment plans. Employing image analysis and machine learning, the research assesses AI's potential to recognize patterns within medical imaging data. The study evaluates the feasibility of integrating AI-based detection into diagnostic workflows. Collaborative efforts with hospitals include collecting annotated breast cancer lymph node data, optimizing workflows, and clinically validating results. Anticipated outcomes aim to highlight AI's crucial role in enhancing early detection and treatment decisions for breast cancer patients. Anticipated results aim to underscore the crucial role of AI in improving early detection and treatment decision-making for breast cancer patients while optimizing efficiency in the operating room nursing workflow.
LAL deficiency is an autosomal recessive lysosomal storage disorder characterized by a genetic defect resulting in a marked decrease or loss in activity of the lysosomal acid lipase (LAL) enzyme. The primary site of action of the LAL enzyme is the lysosome, where the enzyme normally causes the breakdown of lipid particles, including LDL-c and triglycerides. Deficient LAL enzyme activity results in progressive complications due to the lysosomal accumulation of cholesteryl esters and triglycerides in multiple organs, including the liver, spleen, intestine, and the walls of blood vessels. The resulting lipid accumulation in the liver may lead to increased liver fat content and progression of liver disease, including fibrosis and cirrhosis. Lipid accumulation in the intestinal wall leads to malabsorption and growth failure. In parallel, dyslipidemia due to impaired degradation of lysosomal lipid is common with elevated LDL-c and triglycerides and low HDL-cholesterol (HDL-c).

Sebelipase alfa binds to cell surface receptors via glycans expressed on the protein and is subsequently internalized into lysosomes. Sebelipase alfa catalyzes the lysosomal hydrolysis of cholesteryl esters and triglycerides to free cholesterol, glycerol and free fatty acids.